Cefaclor-induced hypersensitivity: Differences in the incidence of anaphylaxis relative to other 2nd and 3rd generation cephalosporins

• Published in: PloS one Vol. 16; no. 7; p. e0254898
• Main Authors: Rhyou, Hyo-In, Nam, Young-Hee, Kim, Su-Chin, Doo, Go-Eun, Ha, Chae-Yeon, Nam, Hee-Joo, Woo, Sung-Dae, Lee, Youngsoo, Jang, Jae-Hyuk, Lee, Hyun-Young, Ye, Young-Min
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 22.07.2021; Public Library of Science (PLoS)
• Subjects: Adverse events; Anaphylaxis; Annual reports; Antibiotics; Biology and Life Sciences; Cefaclor; Cephalosporins; Classification; Clinical trials; Demographics; Demography; Drug dosages; Health insurance; Health risks; Hospitals; Hypersensitivity; Immunology; Insurance; Internal medicine; Medicine; Medicine and Health Sciences; Prescriptions; Side effects
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0254898

Cefaclor, a second-generation oral cephalosporin, is the most frequently prescribed cephalosporin in Korea. Studies, however, have yet to analyze the incidence of cefaclor-associated adverse drug reactions (ADRs), including hypersensitivity (HS), according to total national usage rates. This study aimed to investigate the incidence rates and clinical features of cefaclor ADRs reported to the Korean Adverse Event Reporting System (KAERS) and Health Insurance Review and Assessment Service (HIRA) database for the most recent 5 years. Reviewing the HIRA database, which contains information on all insurance claims, including prescribed medications and patient demographics, we identified the total number of individuals who had been prescribed cefaclor and other cephalosporins including 2 nd generation without cefaclor and 3 rd generation antibiotics from January 2014 to December 2018. Additionally, we retrospectively analyzed all ADRs reported to the KAERS for these drugs over the same study period. Incidence rates for ADRs, HS, and anaphylaxis to cefaclor were 1.92/10,000 persons, 1.17/10,000 persons, and 0.38/10,000 persons, respectively, lower than those to other 2 nd and 3 rd cephalosporins. Among all ADRs, HS (60.9% vs. 43.6% vs. 44.8%, P <0.001) and anaphylaxis (19.8% vs. 4.6% vs. 4.7%, P <0.001) were more common for cefaclor than for other 2 nd and 3 rd cephalosporins. Females, individuals under 65 years of age, concomitant use of drugs, and serious ADRs were more strongly associated with HS to cefaclor than with HS to other 2 nd and 3 rd cephalosporins. In a nationwide database for the Korean population, the incidence of cefaclor-induced ADRs, particularly HS and anaphylaxis, was high. Female sex, age younger than 65 years, and concomitant use of drugs may be associated with HS to cefaclor.